Compare Quanta Services Inc (PWR) vs Summit Therapeutics Inc (SMMT) Price & Performance

Quanta Services (PWR) trades at $639.05, up 2.34% with strong technical momentum and bullish sentiment. The stock shows robust fundamentals with revenue growth from $17.1B in 2022 to $28.5B in 2025, supported by a record $53B backlog. Recent Q2 2026 earnings beat expectations with EPS of $4.24 versus $3.31 expected, while analyst consensus remains strongly bullish with a $811.14 price target.

PWR presents compelling growth potential driven by infrastructure demand and AI-related projects, though elevated valuation multiples (P/E 73.12) and significant capital expenditures pose risks. The company's strong backlog and margin expansion support upside, but investors should monitor execution on large-scale projects and competitive pressures in the construction sector.

Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.

The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.